Increased incidence of clinical EAE at early time points in mice lacking MHCII expression by pDCs and B cells
| Chimeras | Day 12 | Day 16 | Day 20 | Day 24 |
| WT:WT | 0/6 (0%) | 2/6 (33%) | 4/6 (67%) | 6/6 (100%) |
| pIII+IV−/−:WT | 5/8 (62%), *** | 8/8 (100%), *** | 8/8 (100%), ** | 8/8 (100%), NA |
| µMT:WT | 0/6 (0%), NA | 1/6 (17%), ns | 4/6 (67%), ns | 5/6 (83%), ns |
| Chimeras | Day 12 | Day 16 | Day 20 | Day 24 |
| WT:WT | 0/6 (0%) | 2/6 (33%) | 4/6 (67%) | 6/6 (100%) |
| pIII+IV−/−:WT | 5/8 (62%), *** | 8/8 (100%), *** | 8/8 (100%), ** | 8/8 (100%), NA |
| µMT:WT | 0/6 (0%), NA | 1/6 (17%), ns | 4/6 (67%), ns | 5/6 (83%), ns |
EAE was induced by immunization with MOG35–55+CFA in WT:WT, pIII+IV−/−:WT, and µMT:WT chimeras. The numbers and percentages of mice that developed disease at days 12, 16, 20, and 24 are provided. P-values for disease incidence were calculated relative to WT:WT mice using the χ2 test. ns, not significant; **, P < 0.01; ***, P < 0.001; NA, not applicable.